SURUNKALI GLOMERULONEFRIT: UCHRASHI, ASORATLARI VA TUBULOINTERSTITSIAL FIBROZ RIVOJLANISHI (DOLZARBLIGI, XAVF OMILLARI, DIAGNOSTIKASI VA DAVOLASH METODLARI)
Abstract
Surunkali glomerulonefrit (SGN) buyrak kasalliklari orasida yetakchi o‘rinlardan birini egallab, mehnatga layoqatli aholi orasida surunkali buyrak yetishmovchiligining asosiy sabablaridan hisoblanadi. Kasallik uzoq davom etuvchi immun-yallig‘lanish jarayoni bilan kechib, asta-sekin glomerulyar shikastlanish, tubulointerstitsial to‘qimaning zararlanishi va natijada tubulointerstitsial fibroz (TIF) rivojlanishiga olib keladi. TIF surunkali glomerulonefritning eng muhim prognoz omillaridan biri bo‘lib, buyrak parenximasining qaytmas strukturaviy o‘zgarishlari va buyrak funksiyasining progressiv pasayishi bilan kechadi.
References
1. Abbate M., Remuzzi G. Proteinuria as a mediator of tubulointerstitial injury // Kidney International. – 2020. – Vol. 98, № 5. – P. 1127–1136. – DOI: 10.1016/j.kint.2020.06.021.
2. Boor P., Floege J. Renal fibrosis in 2020: new insights into mechanisms and therapeutic targets // Nature Reviews Nephrology. – 2021. – Vol. 17, № 2. – P. 79–94. – DOI: 10.1038/s41581-020-00348-5.
3. Brunskill N.J. Pathogenesis of progressive chronic kidney disease // Clinical Medicine. – 2020. – Vol. 20, № 1. – P. 47–52. – DOI: 10.7861/clinmed.2019-0320.
4. Chung A.C.K., Lan H.Y. MicroRNAs in renal fibrosis: mechanisms and therapeutic implications // Journal of the American Society of Nephrology. – 2020. – Vol. 31, № 2. – P. 270–282. – DOI: 10.1681/ASN.2019080807.
5. Eddy A.A. Fibrogenesis in kidney disease: molecular mechanisms and clinical relevance // Journal of the American Society of Nephrology. – 2020. – Vol. 31, № 3. – P. 431–444. – DOI: 10.1681/ASN.2019070709.
6. Farris A.B., Alpers C.E. What is the best way to measure renal fibrosis? // Kidney International
Supplements. – 2021. – Vol. 11, № 1. – P. 23–32. – DOI: 10.1016/j.kisu.2020.11.004.
7. Fomin V.V., Kotenko O.N. «Хроническая болезнь почек: непризнанные факторы риска и новые клинические рекомендации». Consilium Medicum. 2021; Vol. 23, № 10:736–741. Статья рассматривает традиционные и новые факторы риска ХБП, отражённые в российских клинических рекомендациях 2021 года.
8. Hueper K., Bräsen J.H., Gutberlet M. Diffusion-weighted MRI for assessment of renal fibrosis // Kidney International. – 2020. – Vol. 98, № 3. – P. 675–685. – DOI: 10.1016/j.kint.2020.03.045.
9. KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases // Kidney International Supplements. – 2021. – Vol. 11, № 1. – P. 1–150.
10. Kuppe C., Ibrahim M.M., Kranz J. Decoding myofibroblast origins in human kidney fibrosis // Nature. – 2021. – Vol. 589, № 7841. – P. 281–286. – DOI: 10.1038/s41586-020-2941-1.
11. Lan H.Y. Diverse roles of TGF-β/Smad signaling in renal fibrosis // Nature Reviews Nephrology. – 2021. – Vol. 17, № 7. – P. 470–487. – DOI: 10.1038/s41581-021-00410-4.
12. Meng X.M., Tang P.M.K., Li J., Lan H.Y. TGF-β signaling in renal fibrosis: from mechanisms to therapies // Nature Reviews Nephrology. – 2021. – Vol. 17, № 6. – P. 419–434. – DOI: 10.1038/s41581-021-00404-2.
13. Mise K., Hoshino J., Ubara Y. Prognostic value of tubulointerstitial lesions in chronic glomerulonephritis // Kidney International. – 2020. – Vol. 97, № 5. – P. 1025–1034. – DOI: 10.1016/j.kint.2019.12.018.
14. Perazella M.A. Drug-induced chronic interstitial nephritis // Clinical Journal of the American Society of Nephrology. – 2020. – Vol. 15, № 8. – P. 1173–1182. – DOI: 10.2215/CJN.16191219.
15. Rende U., Riser B.L. Biomarkers of renal interstitial fibrosis // Journal of Physiology. – 2023. – Vol. 601, № 2. – P. 233–248. – DOI: 10.1113/JP282899.
16. Richeldi L., Varone F., Bergna M. Antifibrotic therapies: mechanisms and clinical applications // New England Journal of Medicine. – 2022. – Vol. 386, № 19. – P. 1818–1829. – DOI: 10.1056/NEJMra2114878.
17. Sethi S., Fervenza F.C. Standardized classification and reporting of glomerulonephritis // Kidney International. – 2020. – Vol. 97, № 6. – P. 1114–1127. – DOI: 10.1016/j.kint.2020.01.025.
18. Vaidya V.S., Waikar S.S., Ferguson M.A. Urinary biomarkers of kidney fibrosis // Nature Reviews Nephrology. – 2020. – Vol. 16, № 5. – P. 301–316. – DOI: 10.1038/s41581-020-0253-9.
19. Wang Y., Harris D.C.H. Macrophages in renal fibrosis: mechanisms and therapies // Nature Reviews Nephrology. – 2021. – Vol. 17, № 12. – P. 711–730. – DOI: 10.1038/s41581-021-00446-6.
